Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-06 04:41:25 - browse：75

Illustraion of an abstract genome figure made of dots. -- health coverage from STAT — Adobe

LONDON — A decade ago, the U.K. launched its 100,000 Genomes Project, a major research endeavor that involved sequencing the DNA of that many people to discover how our genes shape our health.

But the initiative wasn’t just focused on sequencing our regular DNA. One arm of the project also entailed decoding the genomes of some participants’ tumors.

In a paper published Thursday morning in the U.K., researchers reported their findings from more than 13,800 solid tumors in adults, detailing that certain tumors were more likely to carry mutations that could inform patient care, whether by steering treatment choices or indicating a potential familial risk. The findings are already influencing clinical practice: It’s becoming standard for patients in the National Health Service with those tumors — including types of brain cancers, sarcomas, and ovarian cancers — to get their tumors sequenced.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Biogen walks away from Aduhelm, years after polarizing approval

focus

WSS

Zyn nicotine pouches become unlikely player in latest culture war

American taxpayers paid $1.8 trillion in health care costs in 2022

Biogen walks away from Aduhelm, years after polarizing approval

Wegovy leads to weight loss. Can it treat depression, too?

Physician assistants need a new name. Here's what it should be

Stories you might have missed in 2023: health, science, medicine

Wikipedia

Wikipedia

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biogen walks away from Aduhelm, years after polarizing approval

Apple is now the first public company to be valued at $3 trillion

A preacher's new calling: Diversifying neuroscience research

The cancer drug shortage isn’t new — and neither are the solutions

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Duchenne breakthrough therapy leaves behind pioneering families

Medicare Advantage overpayments discussion gets experts fired up

In Memoriam: Notable people who died in 2023

Hospital chaplains balance Covid safety with patients’ spiritual needs

explore

Readout Newsletter: The latest on Novavax, Merck, Bluebird

10 reasons why health care startups fail

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Physician assistants need a new name. Here's what it should be

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Zyn nicotine pouches become unlikely player in latest culture war

Wikipedia

focus

hotspot

knowledge